Report Tools

Generics in Italy

Published: August 2013 · Publisher: MarketLine
Generics in Italy industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017).
Report Type Industry Profiles
Language English
Format Electronic (PDF)
Pages37
Frequency Updated Annually
Availability Will be emailed within 1 business day
Reference No. 0109-6814
Price € 259,00
Options
  • Description
  • Companies Mentioned
  • Table of Contents
  • Ask a Question
Introduction

Generics in Italy industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Italy generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

*The Italian generics market had total revenues of $1bn in 2012, representing a compound annual growth rate (CAGR) of 9% between 2008 and 2012.

*Market consumption volume increased with a CAGR of 13.8% between 2008-2012, to reach a total of 16.5% of total pharma volume in 2012.

*The performance of the market is forecast to decelerate, with an anticipated CAGR of 6.1% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $1.3bn by the end of 2017.

Features

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Italy

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Italy

Leading company profiles reveal details of key generics market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Italy generics market with five year forecasts by both value and volume

Macroeconomic indicators provide insight into general trends within the Italy economy

Key Questions Answered

What was the size of the Italy generics market by value in 2012?

What will be the size of the Italy generics market in 2017?

What factors are affecting the strength of competition in the Italy generics market?

How has the market performed over the last five years?

What are the main segments that make up Italy's generics market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Bayer AG, Mylan Inc., Sandoz International GmbH and Teva Pharmaceutical Industries Limited
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 9
Market value 9
Market volume 10
Market Segmentation 11
Geography segmentation 11
Market Outlook 12
Market value forecast 12
Market volume forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 16
Supplier power 17
New entrants 18
Threat of substitutes 19
Degree of rivalry 20
Leading Companies 21
Bayer AG 21
Mylan Inc. 25
Sandoz International GmbH 28
Teva Pharmaceutical Industries Limited 29
Macroeconomic Indicators 33
Country Data 33
Appendix 35
Methodology 35
Industry associations 36
Related research 36

LIST OF TABLES
Table 1: Italy generics market value: $ million, 2008–12 9
Table 2: Italy generics market volume: % of total pharma volume, 2008–12 10
Table 3: Italy generics market geography segmentation: $ million, 2012 11
Table 4: Italy generics market value forecast: $ million, 2012–17 12
Table 5: Italy generics market volume forecast: % of total pharma volume, 2012–17 13
Table 6: Bayer AG: key facts 21
Table 7: Bayer AG: key financials ($) 22
Table 8: Bayer AG: key financials (€) 22
Table 9: Bayer AG: key financial ratios 23
Table 10: Mylan Inc.: key facts 25
Table 11: Mylan Inc.: key financials ($) 25
Table 12: Mylan Inc.: key financial ratios 26
Table 13: Sandoz International GmbH: key facts 28
Table 14: Teva Pharmaceutical Industries Limited: key facts 29
Table 15: Teva Pharmaceutical Industries Limited: key financials ($) 30
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios 31
Table 17: Italy size of population (million), 2008–12 33
Table 18: Italy gdp (constant 2000 prices, $ billion), 2008–12 33
Table 19: Italy gdp (current prices, $ billion), 2008–12 33
Table 20: Italy inflation, 2008–12 34
Table 21: Italy consumer price index (absolute), 2008–12 34
Table 22: Italy exchange rate, 2008–12 34

LIST OF FIGURES
Figure 1: Italy generics market value: $ million, 2008–12 9
Figure 2: Italy generics market volume: % of total pharma volume, 2008–12 10
Figure 3: Italy generics market geography segmentation: % share, by value, 2012 11
Figure 4: Italy generics market value forecast: $ million, 2012–17 12
Figure 5: Italy generics market volume forecast: % of total pharma volume, 2012–17 13
Figure 6: Forces driving competition in the generics market in Italy, 2012 14
Figure 7: Drivers of buyer power in the generics market in Italy, 2012 16
Figure 8: Drivers of supplier power in the generics market in Italy, 2012 17
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Italy, 2012 18
Figure 10: Factors influencing the threat of substitutes in the generics market in Italy, 2012 19
Figure 11: Drivers of degree of rivalry in the generics market in Italy, 2012 20
Figure 12: Bayer AG: revenues & profitability 23
Figure 13: Bayer AG: assets & liabilities 24
Figure 14: Mylan Inc.: revenues & profitability 26
Figure 15: Mylan Inc.: assets & liabilities 27
Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability 31
Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities 32
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.